One endocrine disruption mechanism is through binding to nuclear receptors such as the androgen receptor (AR) and estrogen receptor (ER) in target cells. The concentration of a chemical in serum is important for its entry into the target cells to bind the receptors, which is regulated by the serum proteins. Human sex hormone-binding globulin (SHBG) is the major transport protein in serum that can bind androgens and estrogens and thus change a chemical's availability to enter the target cells. Sequestration of an androgen or estrogen in the serum can alter the chemical elicited AR-and ER-mediated responses. To better understand the chemical-induced endocrine activity, we developed a competitive binding assay using human pregnancy plasma and measured the binding to the human SHBG for 125 structurally diverse chemicals, most of which were known to bind AR and ER. Eighty seven chemicals were able to bind the human SHBG in the assay, whereas 38 chemicals were nonbinders. Binding data for human SHBG are compared with that for rat a-fetoprotein, ER and AR. Knowing the binding profiles between serum and nuclear receptors will improve assessment of a chemical's potential for endocrine disruption. The SHBG binding data reported here represent the largest data set of structurally diverse chemicals tested for human SHBG binding. Utilization of the SHBG binding data with AR and ER binding data could enable better evaluation of endocrine disrupting potential of chemicals through AR-and ER-mediated responses since sequestration in serum could be considered.
Endocrine disrupting chemicals (EDCs) are exogenous compounds that affect the endocrine system of humans and other vertebrates. EDCs sparked intense internationally scientific discussion and debate some 18 years ago (Kavlock et al., 1996) , culminating in issuance of legislation that reauthorized the Safe Drinking Water Act (SDWA Amendments, 1996) and authorization of the 1996 Food Quality Protection Act (FQPA, 1996) mandating that the Environmental Protection Agency (EPA) develop an Endocrine Disruptor Screening Program (EDSP) to evaluate chemicals for possible effects on the endocrine system in humans and wildlife (EPA, 1998; Willett et al., 2011) .
EDCs can exert endocrine activity through a variety of mechanism, including binding to the estrogen receptor (ER) and/or androgen receptor (AR) in the target cells. Extensive ER and AR competitive binding studies have been reported, demonstrating that diverse chemicals can bind either or both ER and AR at a wide range of affinities (Blair et al., 2000; Fang et al., 2001 . Based on the binding data, a variety of quantitative structureactivity relationship (QSAR) models have been developed for evaluation of endocrine activity potential of chemicals through predicting their ER and AR binding affinities (Hong et al., 2002 .
The ability to bind proteins in the endocrine system such as ER and AR is the prerequisite, but is not alone sufficient, for a chemical to exert endocrine activity. Chemicals will not elicit endocrine activity unless they enter the target cells with sufficient concentration. Consequently, in vitro binding data may not reflect well in vivo responses for the some chemicals, even those with high binding affinity in vitro. To accurately assess the endocrine activity potential of chemicals, it is necessary to understand and to measure the binding capability of serum proteins for the EDCs.
The roles of serum binding proteins as direct mediators of hormone transport and action, such as rodent and human sex hormone-binding globulin (SHBG) and alpha-fetoprotein (AFP), have major implications for endocrine activity and its prediction. Therefore, we assayed 125 structurally diverse chemicals for binding to rat AFP, a major transport protein (Hong et al., 2012) . The rat AFP binding data demonstrated that known and potential EDCs are capable of competitively binding to steroidal binding sites on AFP in serum. Even though it has been shown that human, mouse, and rat AFP have similar conserved estrogen binding sites (Mizejewski, 2004) , caution is warranted in attempting to extrapolate from the rat AFP binding data in our previous study to other species, especially humans. Therefore, human serum proteins binding affinity data are needed to assist the human risk assessment of the endocrine activity potential of chemicals.
SHBG is a glycoprotein that transports hormones in the blood and regulates their access to target tissues. SHBG protein is translated from the mRNA of SHBG gene that is in the short arm of chromosome 17 (17p13.1), a region characterized as hotspot for genetic recombination (Berube et al., 1990) . SHBG gene can be expressed in different tissues (Misao et al., 1995) and has genetic variants (Laurent and Vanderschueren, 2014; Prescott et al., 2012) . The human SHBG gene consists of at least two different transcription units that are regulated by different promoters (Selva et al., 2005) . In addition to SHBG, there are many other proteins in blood that are encoded in different genes and can bind to chemicals, including AFP which is encoded in gene AFP located in human genome chromosome 4 (4q13.3), the human orosomucoid (ORM) proteins which is encoded in gene ORM located in human genome chromosome 9 (9q32), the b 2 microglobulin protein which is encoded by the B2M gene located in human genome chromosome 15 (15q21.1), albumin which is encoded in gene ALB located in human genome chromosome 4 (4q13.3) and transthyretin which is encoded in gene TTR located in human genome chromosome 18 (18q12.1). SHBG is a dimeric protein found in blood serum. Each dimer binds to one molecule of steroid, functioning as androgen and estrogen transport protein. AFP is a major plasma protein and the fetal counterpart of serum albumin (Knochenhauer et al., 1998) . AFP binds copper, nickel, fatty acids, and bilirubin as well as estrogens (Hong et al., 2012) . ORM is a key acute phase plasma protein that binds various ligands and influences their distribution and availability in the body, including synthetic drugs such as warfarin, phenprocoumon, and acenocoumarol (Hazai et al., 2010) . The b 2 microglobulin is a serum protein and a component of the class I major histocompatibility complex (MHC) that binds peptide antigens to present them to the immune system (Hebert et al., 2001) . Albumin is the main protein of plasma and binds hormones, fatty acids, bilirubin, Ca and drugs (KraghHansen, 1981) . Transthyretin is a carrier protein that transports thyroid hormones, cerebrospinal fluid, and retinol (vitamin A) in the plasma (Yang et al., 2013) . Hormones such as estrogens and androgens are produced in steroidogenic cells of the gonads, adrenal glands, and placenta (Baker, 2002) . Plasma glycoproteins such as AFP and SHBG transport the hormone molecules in the blood to their target tissues (Dunn et al., 1981) . Human plasma SHBG is the major plasma protein that binds androgens and estrogens and transports them into the target cells (Hammond, 2002 ). Therefore, the SHBG level in the blood influences distribution and access of hormone molecules to target tissues and cells. Understanding the SHBG binding affinity data of EDCs would enable a better assessment of potential human risk of endocrine active chemicals.
Previous investigations on SHBG binding chemicals focused on steroids, including both steroid androgens and estrogens. The architecture of the steroid-binding site and the quaternary structure of the dimer SHBG were determined to show that G domains have jelly roll topology and the steroid intercalates into a hydrophobic pocket within the beta-sheet sandwich (Grishkovskaya et al., 2000) . More crystal structures of SHBG bound with steroids were elucidated, revealing that estradiol, an estrogen steroid, and its active metabolite (2-methoxyestradiol) adopted opposite orientation when compared with 5-alpha-dihydrotestosterone and other androgen steroid molecules Grishkovskaya et al., 2002) . SHBG biding activity of many steroid compounds have been assayed and the data have been extensively used in docking and other in silico modeling studies (Cherkasov et al., 2005b; Nikolic et al., 2012; Saxena et al., 2014) . Relatively, few nonsteroid compounds have been studied for SHBG binding through QSAR studies (Cherkasov et al., 2005a (Cherkasov et al., , 2008 Thorsteinson et al., 2009) . The available SHBG binding activity data of a large number of steroid compounds enabled a better understanding of binding interactions between SHBG and steroid compounds. However, SHBG binding interactions with nonsteroid estrogenic and androgenic compounds have not been well elucidated because of limited experimental data. There is a need for SHBG binding activity data for a large number of structurally diverse compounds to better understand the chemical binding of SHBG and to assist the evaluation of endocrine activity of chemicals.
The objective of the current study was to determine SHBG binding affinities for a large set of chemicals with a wide range of structural diversity, and thereby enable better assessment of the structure-activity relationship. Further comparative analysis with our previously reported AR, ER, and AFP binding data was conducted to evaluate endocrine activity potential of chemicals. In this study, we developed a competitive binding assay to measure the human SHBG binding affinity of a variety of chemicals. Assays were conducted for 125 structurally diverse chemicals spanning 15 chemical classes (Table 1) . The assay results showed that 87 of the 125 test chemicals bound to human SHBG with some steroids exhibiting the highest affinity. Comparisons between the human SHBG, AR, ER, and AFP binding affinities showed low concordance and correlation between SHBG and ER but moderate concordance and correlation between SHBG and AR, indicating that SHBG binding data might be particularly important in assessing of endocrine activity involving AR.
Comparison of data between human SHBG and rat AFP binding affinities showed low concordance between binders and nonbinders and moderate correlation in binding affinity data among binders. Therefore, the human SHBG binding data assayed in this study could enhance our understanding of the binding and transport of EDCs and provide specific data to augment the human risk assessment of endocrine activity potential of chemicals.
MATERIALS AND METHODS
Chemicals. Testosterone (1) and aurin (86) Preparation of HN-charcoal. Four grams of activated charcoal (Norit; Fisher Scientific Co, Fair Lawn, NJ) was suspended in 50 ml deionized water and allowed to settle for several minutes. The water above the charcoal pellet containing fine particles of charcoal was removed. An additional volume of water was added and this process was repeated 8 times. After the eighth washing, the charcoal suspension was centrifuged at 1500 rpm (revolution per minute) for 10 min. The water was decanted and the charcoal was resuspended in 38 ml HN buffer (0.05 M HEPES, 0.05 M NaCl, pH to 7.4) containing 80 mg ovalbumin and 200 mg dextran. The charcoal suspension was stored at 4 C for use in the human SHBG competitive binding assay.
Human SHBG competitive binding assay. Immediately prior to assay, a reaction mixture containing 45 ml HN buffer, 450 ml ovalbumin, 34 ml of human pregnancy plasma, and 22. 
3D structures. The 3D structures of complexes of SHGB, AR, and ER bound with ligands were downloaded from protein data bank (PDB) (http://www.rcsb.org/pdb/). Multimeric structures were reduced to monomeric for superimposition. The 3D structure of complex of rat AFP bound with estrone was generated by molecular dynamics simulations of the complex that was obtained by docking estrone in the rat AFP structure constructed using homology modeling (Shen et al., 2013) .
Superposition of proteins by their cognate ligand. The proteins were aligned by their cognate ligand using the superposition by atom pairs tool in Maestro v 9.5 (http://www.schrodinger.com/ Maestro/). Only the heavy atoms of the cognate ligands were used for the superposition.
Binding pocket surface generation and protein ligand interactions. Maestro v 9.5 and the tools within were used to examine the binding pocket and the protein-ligand interactions. Using the Protein Preparation Wizard tool, the hydrogen atoms were first added to the protein-ligand complexes downloaded from PDB. Then, the hydrogen bonds were assigned using PROPKA and optimized. The molecular surfaces of the binding pockets were generated using the Create Binding Site Surfaces tool with these options: electrostatic potential color scheme and 80% surface transparency. Finally, the protein-ligand interactions were explored using the Contacts and Hydrogen Bonds tool.
Superposition of SHBG-DHT and SHBG-EST complexes. The SHBG-DHT and SHBG-EST complexes were aligned using the Superposition by C-alpha tool in Maestro v 9.5. The residues surrounding the ligands were annotated in the diagram to illustrate their potential similarities/differences between the protein complexes.
Statistical analysis. The statistics analyses, including the similarity calculation, the Pearson correlation analysis, and generation of the corresponding figures, were conducted using the Statistics toolbox in the Matlab version R2013b software (http:// www.mathworks.com/products/matlab/).
RESULTS
Human SHBG binding affinities of 125 chemicals were determined by the competitive binding assay (see "Materials and Methods"). For the human SHBG binders, the IC 50 values (concentration at which 50% binding inhibition is achieved) and the corresponding logRBA values are listed in Steroidal chemicals showed high affinity of binding human SHBG There were 21 chemicals with a steroid structural backbone. The ring-A is a benzene ring for 14 chemicals and cyclohexane or cyclohexene for the remaining 7 chemicals. The structures of these 21 steroidal chemicals are given in Supplementary Figure  S1 . Among the 21 chemicals, only 3 chemicals, mestranol (11), ICI 164-386 (13), and fulvestrant (14), did not exhibit human SHBG binding capability. The remaining 18 steroids showed strong binding affinity for human SHBG. The IC 50 values were determined or extrapolated for the 18 steroidal chemicals from the competition binding curves plotted in Supplementary Figure S2 and listed in Table 1 .
Most flavones did not bind human SHBG Flavones, a class of flavonoids with the structural backbone of 2-phenylchromen-4-one, are mainly found in cereals and herbs. Our previous study showed some flavones can bind to rat AFP (Hong et al., 2012) , ER (Blair et al., 2000) , and AR as shown in Table 1 . To better assess the human risk of endocrine activity potential of flavones, 15 were assayed for human SHBG binding in this study. The structures of the 15 flavones are given in Supplementary Figure S3 . Only three flavones, quercetin (23), apigenin (25), and chrysin (29), bound to human SHBG, and all with weak affinity of logRBA less than À2 as shown in Table 1 (see Supplementary Fig. S4 for the assay curves). The remaining 12 flavones exhibited no SHBG binding capability, though most of them are bound to rat AFP, ER, and AR (Table 1) .
Most flavanones bind human SHBG Flavanones (flavanone and its derivatives) are in another class of flavonoids that have estrogenic and androgenic activity (Blair et al., 2000; . Various plants such as grapefruit, lemons, and limes contain flavanones (Petersona et al., 2006) . Flavanones are derived from flavones by changing the double bond to a single bond between the two carbon atoms in the middle six-member ring. In our previous study (Hong et al., 2012) , 10 natural and synthetic flavanones were analyzed for rat AFP binding capability, of which 7 were rat AFP binders (Table 1 ). The same 10 flavanones (see Supplementary Fig. S5 for the chemical structures) were assayed for human SHBG binding affinity in this study. Seven flavanones bound human SHBG and their IC 50 values are given in Table 1 (see Supplementary Fig. S6 for the assay curves). Moreover, 6 of the 7 also bind rat AFP. The exception, hesperetin (44), has moderate binding affinity to human SHBG while failing to bind rat AFP. In contrast, taxifolin (42) moderately binds rat AFP, while failing to bind human SHBG.
Most isoflavones did not bind human SHBG Isoflavones differ structurally from flavone (22) in the location of the phenyl group. Isoflavones are mainly produced by plants such as soybeans. Because of the similarity in structure to E2, isoflavones can compete with estrogen for the binding sites of the same ER receptor. Our previous study showed moderate ER (Blair et al., 2000) and weak AR binding activity of isoflavones. Surprisingly, in contrast to their ER binding capabilities, 9 of the isoflavones assayed in our previous study (Hong et al., 2012) failed to show binding to the rat AFP (Table 1) . The same 9 isoflavones (see Supplementary Fig. S7 for the chemical structures) were assayed for their capability to bind human SHBG, of which 7 failed to show binding (Table 1) . Only 2, genistein (47) and equol (55), exhibited weak AR and moderate human SHBG binding affinity (see Supplementary Fig.  S8 for detail assay curves).
Most chalcones bind human SHBG
Chalcones are substituted derivatives of chalcone (56) as binding to AR and ER (Blair et al., 2000) . The structures of the 5 chalcones assayed for rat AFP and for human SHBG binding are shown in Supplementary Figure S9 . Only trihydroxychalcone (60) failed to bind to both rat AFP and human SHBG (Table 1) . The other 4 displayed weak binding to both rat AFP and human SHBG. Their logRBA values are given in Table 1 (see Supplementary Fig. S10 for the assay curves from the human SHBG competitive binding assay).
Most coumarin derivatives did not bind human SHBG Coumarin derivatives (natural coumarins or synthetic analogs) contain a coumarin structural backbone, benzopyran-2-one, and bind to ER (Blair et al., 2000) . Six coumarin derivatives (see Supplementary Fig. S11 for the chemical structures) were assayed. Five failed to bind human SHGB, as compared to 4 that fail to bind rat AFP (Table 1) . Only coumestrol (61) bound a human SHBG at moderate affinity (see binding assay curve in Supplementary Fig. S12 ).
Half of the phthalates bind human SHBG Phthalates are esters of phthalic acid and are mainly used as plasticizers added to plastics to increase the flexibility, transparency, durability, and longevity. Some phthalates are prohibited for use in products in the United States because of health concerns, including those associated with endocrine activity (Hallmark et al., 2007) . Human SHBG binding activity was measured for 8 phthalates (see Supplementary Fig. S13 for the chemical structures) that also showed binding activity to AR but not ER (Blair et al., 2000) (Table 1) . Four failed to show binding, whereas the other 4 exhibited weak binding affinity to human SHBG (see Supplementary Fig. S14 for assay curves).
Parabens are human SHBG binders
Parabens are esters of para-hydroxybenzoic acid that are widely used as preservatives by cosmetic and pharmaceutical industries. Parabens have been shown to possess weak estrogenic activity (Blair et al., 2000; Byford et al., 2002) . Six parabens were tested for their binding capability for human SHBG (see Supplementary Fig. S15 for the chemical structures). All 6 parabens bound to human SHBG (assay curves for the 6 parabens are plotted in Supplementary Fig. S16 ). In contrast, only 3 in our previous study (Hong et al., 2012) bound to rat AFP (Table 1) .
Benzophenone derivatives bind human SHBG
We observed that some benzophenone derivatives were able to bind to AR and ER (Blair et al., 2000) . Five benzophenone derivatives (see Supplementary Fig. S17 for the chemical structures) were assayed for human SHBG binding. The resultant IC 50 and logRBA values are listed in Table 1 , and the assay curves are plotted in Supplementary Figure S18 . All 5 assayed displayed human SHBG binding capability, whereas only 3 were rat AFP binders in our previous study (Hong et al., 2012) .
Most diphenylethylene derivatives bind human SHBG
Chemicals with the 1,1-diphenylethylene structural backbone were found to be androgenic and estrogenic in our previous studies (Blair et al., 2000; . Therefore, 5 chemicals with the 1,1-diphenylethylene skeleton shown in Supplementary Figure S19 were assayed. Four of the five displayed human SHBG binding activity. The resultant IC 50 and logRBA values are given in Table 1 (see Supplementary Fig. S20 for assay curves). In contrast, only dihydroxymethoxychlor olefin (87) with a weak IC 50 value of 0.001 mM showed rat AFP binding (Hong et al., 2012) . Interestingly, the only human SHBG nonbinder, nafoxidine (90), exhibited androgenic and estrogenic activity in our previous studies.
Most diphenylmethane derivatives bind human SHBG Diphenylmethane derivatives are chemicals produced commercially in large amounts (2.2 million tons produced worldwide in 2009). Many of them showed androgenic and estrogenic activity in our previous studies (Blair et al., 2000; . Moreover, they have been and remain the subject of considerable public health concerns, particularly bisphenol A (91) (Beronius et al., 2010) and o, p 0 -DDT (95) (Cohn et al., 2007) . Six diphenylmethane derivatives (see Supplementary Fig. S21 for the chemical structures) were assayed for their human SHBG binding capability and 5 exhibited binding affinities as given in Table 1 (see Supplementary Fig. S22 for assay curves). Only p, p'-Methoxychlor (93) failed to show SHBG binding activity; however, all 6 diphenylmethane derivatives previously showed no rat AFP binding activity (Hong et al., 2012) .
Bibenzyl derivatives bind human SHBG
Chemicals with a bibenzyl structural backbone were previously observed to have high binding affinities to ER (Blair et al., 2000) . Therefore, 7 bibenzyl derivatives (structures shown in Supplementary Fig. S23 ) were assayed for human SHBG binding activity. All 7 were human SHBG binders, compared to only 5 that previously exhibited rat AFP binding activity (Table 1) . The assay curves of the 7 chemicals in the human SHBG competitive binding assay are plotted in Supplementary Figure S24 .
Most stilbene derivatives bind human SHBG E-stilbene (trans-1,2-diphenylethylene) derivatives such as diethylstilbestrol (DES) (104) (Dodds et al., 1938) have long been known to be potent estrogenic compounds. DES was withdrawn by the FDA after it was shown to cause cancer in adult females after in utero exposure (Herbst et al., 1971) . Nine stilbene derivatives (see Supplementary Fig. S25 for the chemical structures) were assayed for their human SHBG binding activity. Although only DES (104) exhibited binding to rat AFP with a moderate binding affinity (Table 1) , 8 of the 9 were determined to be human SHBG binders (see Supplementary Fig. S26 for detail assay curves). Of the 9 chemicals, all are moderate to strong ER binders (Blair et al., 2000) and 6 are moderate AR binders (Table 1) .
Mycoestrogens moderately bind human SHBG Mycoestrogens are xenoestrogens produced by fungi and are commonly found in stored grain. Our previous study confirmed that some mycoestrogens bind to both AR and ER. Five mycoestrogens were assayed in this study and their structures are given in Supplementary Figure S27 . The 5 mycoestrogens tested showed moderate human SHBG binding activities (see Supplementary Fig. S28 for assay curves), whereas only 3 exhibited binding to rat AFP (Table 1) .
Phenol is a structural indicator for human SHBG binding Phenol was identified as an important structural alert for ER binding in our previous study (Hong et al., 2002) and similar importance was observed for rat AFP binding (Hong et al., 2012) . Eight chemicals having a phenol structural backbone as shown in Supplementary Figure S29 , and all of which bind to ER, AR, and rat AFP, were assayed for their human SHBG binding. All eight also exhibit human SHBG binding capability (see Supplementary Fig. S30 for assay curves), suggesting phenol to also be viable structural alert for human SHBG binding.
Comparison of binding activity between human SHBG and AR
Among the 125 chemicals assayed for human SHBG binding activity in this study, 65 chemicals also have been assayed for AR binding activity using a recombinant AR competitive binding assay . A comparison of the SHBG and AR assays resulted in the confusion matrix (Lewis and Brown, 2001) of Table 2 . The overall concordance in assignments of either binders or nonbinders between the two assays was 84.6% (55 of 65). The probability of AR binders that did not show human SHBG binding activity, 8.9% (5 of 56), was slightly higher than that of human SHBG binders that failed to exhibit AR binding activity, 7.3% (4 of 55). However, the pairwise linear correlation coefficient between binding affinity data for the 51 chemicals that bind both human SHBG and ER was moderate, 0.694, as depicted by the circles in Figure 1A . The linear regression model, logRBA(AR) ¼ À1.175 þ 0.449*logRBA(SHBG), fitted the data (the dash line in Fig. 1A) .
To understand the binding activity of chemicals to SHBG and AR at molecular level, the 3D structures of SHBG and AR bound DHT were compared. Figure 2A gives a view of the 3D structures of complex AR-DHT (PDB ID: 3L3X) (Zhou et al., 2010) in gray and SHBG-DHT (PDB ID: 1D2S) (Grishkovskaya et al., 2000) in maroon that are superimposed by their cognate DHT molecules with carbon colored green and oxygen colored red. The androgen, DHT, entirely fits within the completely enclosing ligand binding pocket of AR as depicted by Figure 2B and also sits in the ligand binding pocket of SHBG, which is open to the bulk solvent, as shown in Figure 2D . The similar binding pockets may explain the moderate concordance in binders for SHBG and AR. Closer inspection of the ligand binding pockets suggested rational reasons for differences in the interactions with DHT. Most of the residues of the AR ligand binding pocket are hydrophobic, whereas a few residues play key roles for ligand binding through forming hydrogen bonds; that is, ASN705 and THR877 allowed hydrogen bonding with the hydroxyl group at the D ring of DHT as shown in Figure 2C . Compared to AR, the SHBG ligand binding pocket with more polar residues more easily formed hydrogen bonds with ligands. As with AR, ASP65 and ASN82 formed hydrogen bonds with the hydroxyl group at the D ring of DHT as depicted in Figure 2E . However, another hydrogen bond also formed between the carbonyl group at the A ring of DHT and the residue SER42 of SHBG (Fig. 2E) , whereas the carbonyl oxygen was too far ( $ 4.3 Å ) from the AR binding pocket to form a hydrogen bond, as shown in Figure 2C .
Comparison of binding activity between human SHBG and ER Among the 125 chemicals assayed for human SHBG binding activity in this study, 114 chemicals also have been assayed for The concordant assignments of binders and nonbinders are in bold and the discordant assignments in italics. ER binding activity using the ER obtained from uterine cytosol of nonpregnant adult Sprague Dawley rats (Blair et al., 2000) . A comparison of the two assays resulted in the confusion matrix of Table 3 . The overall concordance in assignments of binders or nonbinders between the two assays was 71.1% (81 of 114). The probability of ER binders that did not show human SHBG binding activity, 23.6% (21 of 89), was higher than that of human SHBG binders that failed to exhibit ER binding activity, 15.0% (12 of 80). However, the pairwise linear correlation coefficient between binding affinity data for the 68 chemicals that bind both human SHBG and ER was low, 0.318, as depicted by the diamonds and squares in Figure 1B . Different from other steroids, dihydrotestosterone (15), 3b-androstanediol (19) and 3a-androstanediol (18) showed high affinity to bind SHBG but were very weak ER binders (the squares in Fig. 1B) . After removing the three chemicals, the pairwise linear correlation by their cognate estradiol molecules in blue as depicted in Figure 3A . Like the AR, the ER also comprises largely of alphahelices connected by loops. Figure 3B shows the bound estradiol in the completely enclosed pocket of the ER. In contrast to the AR-DHT complex, empty spaces were available above and below the plane of the estradiol steroid core, particularly at the C and D rings, potentially explaining why some chemicals bind ER but not SHBG. Figure 3C depicts the interactions between ER and estradiol. Although the ER binding pocket was also lined primarily with hydrophobic residues, less hydrophobic contacts could be formed due to the relatively loosely bound state of the estradiol. Among polar residue, HIE524 (epsilon protonated HIS) formed a hydrogen bond with the hydroxyl group at the D ring of estradiol, whereas GLU353 and ARG394 formed hydrogen bonding interactions with the hydroxyl group at the A ring. Figure 3D shows the binding pose of estradiol in the binding pocket of SHBG. Unlike the SHBG-DHT complex, the SHBG-estradiol binding pocket was not exposed to the bulk solvent; this difference can be attributed to the missing stretch, PRO130-ARG135, in the SHBG-DHT complex that arches over the binding pocket like a lid. Figure 3E depicts the binding interactions The concordant assignments of binders and nonbinders are in bold and the discordant assignments in italics. The concordant assignments of binders and nonbinders are in bold and the discordant assignments in italics.
between estradiol and SHBG. The replacement of the carbonyl group at the A ring with a hydroxyl group increased the potential for hydrogen bonding to occur. Interestingly, when compared with the SHBG-DHT complex, the estradiol molecule was found to flip in relation to the binding position of DHT. The D ring in estradiol, instead of forming hydrogen bonds with ASN82 and ASP65, formed a hydrogen bond with SER42 and the backbone carbonyl of VAL105. On the other hand, the hydroxyl group at the A ring in estradiol formed hydrogen bonds with ASP65 and ASN82.
Comparison of binding activity between human SHBG and rat AFP All the 125 chemicals assayed for human SHBG binding activity in this study have also been assayed for rat AFP binding activity using amniotic fluid obtained from timed-pregnant Sprague Dawley rats (Hong et al., 2012) . A comparison of the two assays resulted in the confusion matrix in Table 4 . The overall concordance in assignments of binders or nonbinders between the two assays was 61.6% (77 of 125), lower than that between human SHBG and ER. Moreover, 84.2% (48 of 57) of rat AFP binders were confirmed as human SHBG binders, whereas only 55.2% (48 of 87) of human SHBG binders showed rat AFP binding activity. The pairwise linear correlation coefficient between binding affinity data for the 48 chemicals that bind both human SHBG and rat AFP was a moderate 0.669, as depicted by the triangles in Figure 1C . A linear regression model, logRBA(AFP) ¼ À0.205 þ 0.602*logRBA(SHBG), fitted the data (the dash line in Fig. 1C ). The 3D structure of the complex AFP-Estrone (AFP and estrone color-coded in turquoise and orange, respectively) was generated in our previous homology modeling and molecular dynamics simulation study (Shen et al., 2013) and was superimposed with the crystal structure of complex SHBG-DHT (with SHBG and DHT color-coded in maroon and green, respectively) (PDB ID: 1D2S) (Grishkovskaya et al., 2000) by their cognate ligands as shown in Figure 4A . AFP is composed of largely alpha-helices connected by loops, but its ligand binding domain is significantly larger than that of either AR or ER. Figure 4B shows bound estrone in the binding pocket of AFP. The ligand was found to rest against a surface of the relatively spacious binding pocket. Figure 4C depicts the relatively nonspecific AFP-estrone interactions, where hydrophobic contacts were found to be the sole attractive forces that anchor the ligand in place.
In contrast to the moderate concordance in binder/nonbinder assignment between human SHBG and AR (Table 2) , concordance between rat AFP and AR was low, as shown in Supplementary Table S1 . Moreover, for the same binders, affinity for binding AR was generally much lower than affinity for binding AFP, as depicted in Supplementary Figure S31 . Interestingly, the correlation between ER and AR binding affinity data as shown in Supplementary Figure S32 was lower than those between SHBG and the other three proteins as depicted in Figure 1 . Although ER and AR contain more alpha-helices and have similar folds (very different compared with the structure of SHBG that has a lot of beta sheets), an expected higher correlation has not been obtained. We speculate that chemical binding of a protein is determined by the characteristics of its ligand binding pocket rather by its overall folding that is usually related with the biological function of the protein. The comparison of the binding pockets of ER and AR revealed that the binding pockets are different in shape and chemical properties of the amino acid residues as depicted in Supplementary  Figure S33 .
DISCUSSION
Human SHBG is a plasma protein that binds and transports hormones such as androgens and estrogens into target tissues and cells (Hammond, 1995; Joseph, 1994; Siiteri et al., 1982) . SHBG can sequester androgens and estrogens or EDCs in circulating serum, thus regulating the amount of hormones available to modulate endocrine activity in tissues. SHBG binding affinities could therefore be important parameters for estimating chemicals' potential for endocrine activity in humans. A chemical with low affinity to human SHBG but high affinity to AR or ER could exert strong hormone stimulation, whereas a chemical with a high binding affinity to human SHBG could be tightly bound and not enter the target cells, inducing less endocrine activity. To better understand the potential for endocrine disruption in humans, 125 chemicals from 15 structural classes were evaluated for human SHBG binding capability using an assay in which the chemicals compete with 1,2,4,5,6,7-[ 3 H]-dihydrotestosterone for binding to SHBG in human pregnancy plasma. To the best of our knowledge, this is the largest data set in terms of both number and diversity of chemicals for which binding to human SHBG has been measured. Furthermore, most of the chemicals assayed for human SHBG binding in this study also were evaluated for their binding to ER, AR, and rat AFP in our previous studies (Blair et al., 2000; Hong et al., 2012) . Comparing human SHBG binding data with that for ER, AR, and rat AFP binding data provide rational bases for understanding of similarities and differences of binding mechanisms and structural features among the receptors, knowledge that will be valuable for assessing endocrine disrupting potential of chemicals. Importantly, estrogens had very different orientations in the binding pocket of SHBG than androgens. Figure 5 illustrates the differences in binding modes between estradiol and DHT in the binding pocket of SHBG. Figure 5A shows the remarkably well superimposed complexes of SHBG and DHT (yellow and green, respectively) and SHBG and EST (maroon and blue, respectively), not only in the beta sheets region but in the loop regions as well. Figure 5B indicates that DHT and EST are bound in a reverse manner, where the A ring with D rings are flipped (as labeled in Fig. 2C ). The majority of the residues lining the SHBG pocket in these two complexes were very similar with only minor rotational differences in residues ILE141, Met107 and Ser128 and TRP84. The observed differences in binding modes for estrogens and androgens might imply that SHBG binds estrogens and androgens in different ways that may impact the utilization of SHBG binding data in assessing endocrine activity mediated by AR and ER.
Human SHBG is reported to be associated with many pathological conditions, including endometrial cancer (Nisker et al., 1980) , ovarian dysfunction (Hogeveen et al., 2002) , breast cancer (Fortunati et al., 2010) , nodal metastases (Salonia et al., 2009 ), prohyperglycemia (Arias-Santiago et al., 2011 ), preeclampsia (Valdés et al., 2012 , osteoporosis (van Pttelgergh et al., 2004; Rapuri et al., 2004 ), Alzheimer's disease (Muller et al., 2010) , diabetes mellitus (Chen et al., 2012; Cottrell et al., 2014) , and some cardiovascular diseases (Canoy et al., 2014; Pascual-Figal et al., 2009) . Therefore, human SHBG binding data could not only improve human risk assessment of the endocrine disrupting potential of chemicals, but also aid in the development of drugs for the treatment of diseases associated with low endogenous sex hormone bioavailability (Cherkasov et al., 2005a) . That is, chemicals that competitively bind human SHBG could prevent the formation of human SHBG-hormone complexes by increasing sex steroid hormone levels to appropriate values. Nonsteroidal chemicals that bind human SHBG potentially could be useful alternatives or adjuncts to current hormone replacement therapies.
Human blood serum contains about 7% proteins which mainly consist of albumin (more than half), globulin (some onethird), and fibrinogen (about one-fifteenth). The serum proteins serve many functions, including transport of hormones, vitamins and other chemicals within and between cells and organs. SHBG is a serum protein that binds to hormones and other chemicals (Anderson, 1974) and thus binding affinity to SHBG could assist evaluation of endocrine disrupting potential of chemicals when combined with AR and ER binding affinities. However, we should be aware of the confounding potential of the SHBG binding data because other chemical binding proteins in the serum could bind the chemicals. We also noted that using only SHBG binding data may lead to under assessing serum protein binding of chemicals. More effective evaluation of endocrine disrupting potential of chemicals will be possible when binding of chemicals for a broader spectrum of serum proteins are available.
The roles of serum binding proteins such as human SHBG as direct mediators of hormone function have major implications for endocrine disruption and its prediction. One primary mechanism of endocrine disruption is through receptor binding, where access to target tissues is a prerequisite to endocrine activity. Our data demonstrate that known and potential EDCs are capable of competitively binding to steroidal binding proteins such as human SHBG, protectively mitigating target tissue exposure. Moreover, sequestering EDCs in serum will boost detoxification in the liver. However, it is possible that binding of chemicals to human SHBG could result in displacement of the endogenous ligand, thereby exposing target tissues to higher endogenous hormone levels than normally observed and potentially resulting in adverse effects. Therefore, we suggest that human SHBG binding data can be combined with AR and ER binding data in prioritizing EDCs for subsequent in vivo assays: EDCs with high binding affinity to AR and ER, but low binding to human SHBG, should have higher testing priority than those with high binding affinity to human SHBG.
In summary, our study demonstrated the ability of chemicals with diverse structural characteristics to bind human SHBG, a serum steroid binding protein. Although the specific role of human SHBG in relation to endocrine disruption requires further analysis, the data reported here enable a better understanding of binding interactions and mechanisms between chemicals and human SHBG. This knowledge will shed light on the understanding of the roles of the serum binding proteins in modulating endocrine disruption and improve assessments of endocrine disruption potential of chemicals.
